Abstract
NAD+ level has been associated with various age-related diseases and its pharmacological modulation emerges as a potential approach for aging intervention. But human NAD+ landscape exhibits large heterogeneity, and the lack of rapid, low-cost assays limits the establishment of NAD+ baseline and the development of personalized therapies, especially for those with poor responses towards conventional NAD+ supplementation. Here, we developed an automated NAD+ analyzer for the rapid measurement of NAD+ with 5 μL of capillary blood using a recombinant bioluminescent sensor protein and an automated optical reader. The minimal invasiveness of the assay allowed a frequent and decentralized mapping of real-world NAD+ dynamics. We showed that sports and NMN supplementation can increase blood NAD+ levels and that male on average has higher NAD+ than female before the age of 50. We further revealed the long-term stability of human NAD+ baseline over 100 days and identified the major real-world NAD+-modulating behaviors.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ChiCTR2000040222
Funding Statement
This study was funded by Shenzhen Science, Technology Program (ZDSYS20210623091810032), National Key R&D Program of China (2020YFC2002904, 2021YFF1200302) and Research Projects on Key Areas of General Colleges and Universities, Department of Education of Guangdong Province (2022ZDZX2071) Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, and Celfull Hebe Fund for the Biological Study of Aging
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Guangzhou Sport University (ethics approval number: 2020 LCLL-003) and Institutional Review Board of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences (ethics approval number: SIAT-IRB-210915-H0575)gave ethical approvals for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵4 Lead contact
Data Availability
All data produced in the present study are available upon reasonable request to the authors
